Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 1:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Escherichia Coli Clear all
Completed Not applicable Interventional

Prevention of Urinary Tract Infection (UTI) in Persons With Spinal Cord Injury (SCI)

NCT00309114
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
bacterial interference
Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
15 Years to 64 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 29, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects

NCT00654108
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Ciprofloxacin, Peru-15-pCTB, Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Sep 29, 2026, 1:46 AM EDT
Withdrawn No phase listed Observational

Ampicillin-sulbactam Resistant E.Coli at UPMC

NCT00619580
View directory record Official record
Conditions
Positive E Coli Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 7, 2014 · Synced Sep 29, 2026, 1:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pre-Study of Wild Type Enterotoxigenic E. Coli (ETEC) Strain for Verification of a Planned Challenge Dose

NCT06290089
View directory record Official record
Conditions
ETEC Diarrhea
Interventions
Enterotoxigenic E. coli (ETEC) strain
Other
Lead sponsor
Scandinavian Biopharma AB
Industry
Eligibility
18 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 29, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of dmLT ID Vaccination in Healthy Adults

NCT02531685
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2020 · Synced Sep 29, 2026, 1:46 AM EDT
Completed Phase 1 Interventional

E. Coli for Prevention of Catheter UTI in SCI Patients

NCT00458471
View directory record Official record
Conditions
Urinary Tract Infection(UTI)
Interventions
Insertion of a urinary catheter coated with benign E. coli
Device
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2007 · Synced Sep 29, 2026, 1:46 AM EDT
Recruiting Not applicable Interventional

Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection

NCT05219110
View directory record Official record
Conditions
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Interventions
Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
Other
Lead sponsor
University of Calgary
Other
Eligibility
9 Months to 21 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 29, 2026, 1:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli (EXPECT-1)

NCT04087681
View directory record Official record
Conditions
E.Coli Infections
Interventions
Not listed
Lead sponsor
MJM Bonten
Other
Eligibility
60 Years and older
Enrollment
4,479 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Sep 29, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Sublingual dmLT for ETEC

NCT02052934
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2019 · Synced Sep 29, 2026, 1:46 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in Adults

NCT03038243
View directory record Official record
Conditions
Shigella Sonnei Dysenteries
Interventions
Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT), Shigella flexneri 2a whole cell (Sf2aWC) vaccine, Placebo
Biological · Other
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Sep 29, 2026, 1:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Urinary Bactericidal Activity of 4 Doses of Levofloxacin Against Fluoroquinolone-Resistant E. Coli

NCT00376376
View directory record Official record
Conditions
Healthy Volunteers
Interventions
levofloxacin at 250, 500, 750, and 1000 mg doses
Drug
Lead sponsor
Michigan State University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 26, 2008 · Synced Sep 29, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects

NCT05277350
View directory record Official record
Conditions
E.Coli Infections, Bloodstream Infection
Interventions
SNIPR001, Placebo
Drug
Lead sponsor
SNIPR Biome Aps.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 29, 2026, 1:46 AM EDT
Completed No phase listed Observational

Perinatal Transmission of MDR Bacteria

NCT06148480
View directory record Official record
Conditions
E. Coli Infection, Multi-antibiotic Resistance
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 29, 2026, 1:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Experiment of Helicobacter Pylori Transmission

NCT00550368
View directory record Official record
Conditions
Infection, Achlorhydria
Interventions
Biological intervention: Enteropathogenic E. coli
Biological
Lead sponsor
Stanford University
Other
Eligibility
35 Years to 59 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Sep 29, 2026, 1:46 AM EDT
Completed Phase 2Phase 3 Interventional Results available

An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

NCT04145531
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia
Interventions
IM JZP-458, IV JZP-458
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 29, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant

NCT03922061
View directory record Official record
Conditions
Polio
Interventions
dmLT, fIPV
Biological
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 29, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Results available

Bacterial Interference for Prevention of Catheter-Associated UTI: Geriatric Pilot Study

NCT00554996
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
E. coli 83972 coated urinary catheter
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Sep 29, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge

NCT03040687
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Anti CS6 BSIgG product (Lot PD1601105CS), Anti B7A BSIgG product (Lot PD1601132ET), Bovine Immunoglobin Negative Control (Lot PD161071NC), B7A- CS6-expressing ETEC challenge strain
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 29, 2026, 1:46 AM EDT
Completed Phase 2 Interventional Results available

A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy

NCT01643408
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions
asparaginase Erwinia chrysanthemi
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Los Angeles, California • Orange County, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 29, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-finding Study of WS6788A, DS37-4 and H10407 Enterotoxigenic Escherichia Coli (ETEC) Challenge Strains

NCT00198796
View directory record Official record
Conditions
Diarrhea
Interventions
H10407
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 45 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 29, 2026, 1:46 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Enteroaggregative E.Coli (EAEC)

NCT00362869
View directory record Official record
Conditions
Escherichia Coli Infections
Interventions
Levofloxacin, Placebo, Enteroaggregative E. coli (EAEC)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 25, 2016 · Synced Sep 29, 2026, 1:46 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701

NCT03576183
View directory record Official record
Conditions
Enterotoxigenic Escherichia Coli Infection, Diarrhea
Interventions
VLA1701, Placebo, Challenge Strain
Biological · Other
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years to 49 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Sep 29, 2026, 1:46 AM EDT
Completed No phase listed Observational

Quinolone Resistance in Bloodstream Isolates of Escherichia Coli

NCT00449735
View directory record Official record
Conditions
Bacterial Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Sep 29, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Low-dose Challenge Model With Enterotoxigenic E Coli

NCT00844493
View directory record Official record
Conditions
Diarrhea
Interventions
E coli strain H10407 and buffer, E coli H10407 and buffer
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Sep 29, 2026, 1:46 AM EDT